1. The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis

2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. It will also include a discussion of off-label exposure to medications.

3. Rising Prevalence of MS and Proportion of Women With MS Who Become Pregnant

4. 3 Different Patients With MS and Family Planning Scenarios

5. Genetic Risk for MS: Environmental Factors Play a Greater Role

6. Expert Recommendations for Julie and Mary

7. Pregnancy-Related Relapse in Multiple Sclerosis: PRIMS Study

8. Patient Case: Julie

9. The Dilemma of MS Treatment and Pregnancy

10. EMA Criteria for Medicinal Product Risk for Fetal Malformations

11. The Injectables: Interferon and Glatiramer Acetate

12. Findings From the European Interferon Beta Pregnancy Registry and Population-Based Registries in Finland and Sweden

13. Oral Therapies: Dimethyl Fumarate Risk in Pregnancy

14. Oral Teriflunomide: Clinical Study and Post-Marketing Data for Pregnancy Outcomes

15. Patient Case: Mary

16. Case Reports of Rebound After Natalizumab and Fingolimod Withdrawal

17. Use of Corticosteroids to Treat Relapse During Pregnancy

18. Fingolimod and Pregnancy: Incidence of Malformations and Relapses

19. Alemtuzumab and Pregnancy: Findings From the German MS and Pregnancy Registry, Plus Cases From Norway and Serbia

20. Anti-CD20 Monoclonal Antibodies and Pregnancy

21. B-Cell Depleting Antibodies: B-Cells Should be Checked in Babies of Exposed Mothers

22. Pregnancy Outcomes After Cladribine Exposure

23. Pregnancy and Cladribine: EU Label

24. Mutagenic Cancer Treatments and Risk of Congenital Anomalies in Offspring

25. Natalizumab and Pregnancy Outcomes

26. Risk of Natalizumab Exposure or Withdrawal

27. John's Fatherhood and Potential Risk of MS Medication

28. Pregnancy and MS: Outcomes and Delivery

29. Breastfeeding vs Not Breastfeeding: Effect on Relapses

30. Data for DMT Use During Lactation and Recommendations for Management Strategies in the Postpartum Period

31. MS and Family Planning: Conclusions

32. MS and Family Planning: Conclusions (cont)

33. Abbreviations